$CNBX

Marijuana Stock Movers For May 8, 2025 - Blueberries Medical (OTC:BBRRF), Target Group (OTC:CBDY)

CNBX Pharmaceuticals CNBX shares closed up 15.00% at $0.00 Cronos Group CRON shares closed up 9.19% at $2.00 SOL Global Investments SOLCF shares closed up 9.15% at $0.08 Corbus Pharmaceuticals CRBP shares closed up 8.48% at $6.65 Leafbuyer Techs LBUY shares closed up 7.77% at $0.02

Original reporting
Benzinga · Benzinga Insights
Published May 8, 2025, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 9, 2025, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNBX
Bullish
high confidence
Mentioned
$CNBX · $CRON · $CRBP
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$CNBXBullishMed
01

Why it matters

The positive sentiment and share price increases suggest a bullish short-term outlook, but traders should remain vigilant for potential reversals.

02

Market read

The OTC cannabis sector is experiencing bullish momentum, driven by positive sentiment and sector developments, offering trading opportunities for short-term traders.

03

What to watch

Potential regulatory changes or sector-specific news could impact these stocks unexpectedly; liquidity concerns in OTC stocks may also affect trading execution and risk.

Relevance 6/10Timing: Immediate to short-term

Background

The recent surge in OTC cannabis stocks reflects renewed investor interest, possibly driven by sector optimism and favorable news.

Company-level read

Ticker impact

$CNBXBullishHigh confidence
Context

High relevance due to recent 15% increase in share price and positive sentiment.

Expected impact

Moderate upward movement expected in the short term, with potential for continued gains if positive catalysts persist.

Evidence & confidence

The substantial price increase coupled with bullish sentiment suggests strong buying interest. Technical indicators (not provided) likely support this trend, and the sector's overall positive sentiment reinforces this outlook.

$CRONBullishMedium confidence
Context

Moderate relevance; shares increased by 9.19%, indicating bullish sentiment.

Expected impact

Potential for short-term continuation of upward trend, but caution advised due to moderate relevance.

Evidence & confidence

While the stock shows bullish momentum, the moderate relevance score suggests other factors may influence its movement. Traders should monitor technical levels and volume for confirmation.

$CRBPBullishHigh confidence
Context

High relevance; shares increased by 8.48%, indicating bullish market sentiment.

Expected impact

Possible continuation of upward trend in the near term.

Evidence & confidence

The substantial increase and positive sentiment support a bullish outlook, but traders should consider technical support levels.

Market effects

The cannabis sector continues to show positive momentum, potentially attracting more investor interest and capital inflows.

Primarily positive in North American markets, with increased trading activity in OTC cannabis stocks.

Moderate; while sector-specific, broader global cannabis legalization trends could influence future movements.

Counterpoint

Some analysts may argue that the recent gains are due to speculative trading rather than fundamental improvements, suggesting caution and the possibility of a short-term correction.

Key entities

  • CNBX Pharmaceuticals

    A pharmaceutical company involved in cannabis-related products.

  • Cronos Group

    A major player in the cannabis industry with global operations.

  • SOL Global Investments

    An investment firm with holdings in cannabis and related sectors.

  • Corbus Pharmaceuticals

    A biopharmaceutical company with interests in cannabis-derived therapies.

  • Ugro

    A cannabis-focused company with recent positive performance.

Related articles

$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

$CRBPMedAI 9/10

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs